Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer’s Retacrit Finally Clears US FDA, But Biosimilar’s Launch Date Is Still Unclear

May 16 2018

• By Sue Sutter

FDA Approved typed words on a vintage typewriter

Related Content

Biosimilar Denied: Hospira's Retacrit Could Head Back To FDA In First Half 2016

Oct 28 2015

Epogen Biosimilar Jury Verdict May Ignite New 'Safe Harbor' Battle

Sep 27 2017

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

Sep 21 2017

Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes

Jun 22 2017

Related Companies

Pfizer Inc.

Amgen, Inc.

Johnson & Johnson

Hospira, Inc.

CSL Vifor

Celltrion, Inc.

Additional Topics

United States Biosimilars Approvals Legal Issues Intellectual Property Regulation Blood & Coagulation Disorders Cancer Renal BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.